TH is associated with higher biological drug concentrations than MH in CD. Clinical trials are needed to further investigate whether dose escalation in patients with MH is helpful to achieve TH and evaluate the cost-effectiveness of this treat-to-TH strategy.
Han et al. (Thu,) studied this question.